trastuzumab
'Vast Majority' of Cancer Patients Lack Access to Essential Drugs Despite Advances, Says WHO Expert
Premium
Using Herceptin as an example, Andre Ilbawi detailed the challenges low- and medium-income countries face in accessing essential therapies.
Roche Highlights Inavolisib Market Prospects as Q1 Revenues Fall 6 Percent on Currency Headwinds
Premium
The Swiss drugmaker expects a decision from the FDA on inavolisib as a treatment for PIK3CA-mutated breast cancer by the end of the year.
In the first half of 2023, the Swiss biotech reported growth in sales of several precision oncology medicines including its HER2-targeted and immunotherapy products.
Merck Asks FDA to Limit Keytruda Combo Approval in HER2-Positive Gastric Cancer to PD-L1 Expressors
A new subgroup analysis from the Keynote-811 trial showed that the benefit of adding Keytruda to Herceptin and chemo was limited to patients with PD-L1-positive tumors.
FDA Approves Seagen's Tukysa, Genentech's Herceptin for HER2-Positive Colorectal Cancer Patients
The agency granted the dual anti-HER2 regimen accelerated approval as a second-line option for advanced colorectal cancer patients based on data from the MOUNTAINEER trial.